However, those inhibiting PI3K-AKT-mTOR and KRAS-ERK/MAPK oncogenic pathways may suppress cancer and immune cells alike, leading to unintended consequences, like impaired T-cell function, and weakened immune responses. Here, KRAS is linked to cancer.